Efficacy and safety of S-ketamine in pain management for breast cancer patients undergoing modified radical mastectomy: a meta-analysis of randomized controlled trials

Abu-Hussein B 1 , Elrosasy A 2 , Samy H 3 , Ali AS 4 , Alijla SS 5 , Bitar AN 6 Show all authors , Gamal I 4

Affiliations 

  • 1 Orthopedic Department University Hospital Southampton, Southampton, England
  • 2 Faculty of Medicine, Cairo University, Cairo, Egypt. 10912022103193@stud.cu.edu.eg
  • 3 Faculty of Physical Therapy, Modern University for Technology and Information, Cairo, Egypt
  • 4 Faculty of Medicine, Al-Azhar University, Cairo, Egypt
  • 5 Department of Anesthesiology, Algerian Hospital, Palestine Military Medical Services, Bethlehem, Palestine
  • 6 Department of Clinical Pharmacy, Faculty of Pharmacy, Universiti Sultan Zainal Abidin, Jalan Tembila, 22200, Besut, Terengganu, Malaysia
Clin Transl Oncol, 2025 Feb 05.
PMID: 39907885 DOI: 10.1007/s12094-025-03847-8

Abstract

BACKGROUND: Breast cancer remains a leading cause of morbidity and mortality among women worldwide. According to the recent statistics by World Health Organization (WHO), it is the leading cause of death from cancer in women worldwide and it is the most frequently diagnosed cancer. This meta-analysis aims to systematically evaluate the efficacy and safety of S-ketamine in patients undergoing modified radical mastectomy.

METHOD: We searched five databases; PubMed, Scopus, Science Direct, Web of Science, and Medline Plus. We included six studies. The applicable outcomes for meta-analysis about efficacy and safety of S-ketamine in patients undergoing modified radical mastectomy.

RESULTS: Six RCTs included in our meta-analysis found that Esketamine group had a statistically significant lower VAS score after 4 h, after 6 h, after 24 h, after 48 h; (MD = -1.54; 95% CI [-1.65, -1.42], P 

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications